Beta Bionics announced today that a trial of its iLet bionic pancreas met key endpoints, including reduced HbA1c.
Dr. Roy W. Beck and clinical investigators presented the results of the multi-center, randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans.
Get the full story at our sister site, Drug Delivery Business News.